ZIOPHARM Oncology Inc (NASDAQ:ZIOP) stated gains of 551,281 shares or 1.5% in the short interest. The short interest registered from 37,017,176 on May 31,2016 to 37,568,457 on June 15,2016. In terms of floated shares, the shorted positions stood at 31.8%. The stock has been averaging 2,174,437 shares daily in trading and would need 17 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP): The stock opened at $5.75 on Friday but the bulls could not build on the opening and the stock topped out at $6.02 for the day. The stock traded down to $5.61 during the day, due to lack of any buying support eventually closed down at $5.64 with a loss of -7.08% for the day. The stock had closed at $6.07 on the previous day. The total traded volume was 3,180,889 shares.
The company shares have dropped -51.13% from its 1 Year high price. On Nov 10, 2015, the shares registered one year high at $14.93 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $6.86 and the 200 Day Moving Average price is recorded at $7.29.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has tumbled 2.76% during the past week and has dropped 23.68% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.14%. ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has underperformed the index by 21.37% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).